The head of B.C.’s medical association
says the federal government is failing Canada’s doctors by not providing
meaningful guidelines on how to talk to their patients about medical
marijuana prescriptions in the absence of reliable clinical studies.
Bill
Cavers says doctors across Canada are being bombarded with information
on medical marijuana by the same companies producing the drug, a clear
conflict of interest. Health Canada, which does not endorse medical
marijuana’s use, should stop the practice, said Dr. Cavers, who wants an
independent process to better educate medical professionals about the
benefits and dangers of the drug.
Dr. Cavers, president of Doctors of BC,
which represents the province’s 12,000 physicians, said the way the new
system of medical marijuana regulation continues to roll out “is a
free-for-all.”
“Here we have providers
who have a vested interest in promoting the product being the ones to
potentially train professionals in how to provide that product,” Dr.
Cavers said. “That’s analogous to a pharmaceutical company training me
in the use of their product.
“While it may provide me information, it’s not unbiased.”
Last
year, the federal government overhauled its system of small licensed
growers supplying themselves and other patients in favour of
commercial-scale producers that can sell directly to people prescribed
the drug.
The Canadian Medical
Association has consistently opposed the new regime because its doctors
are now forced to assess their patient’s treatment needs and prescribe
set dosages, while under the old system they merely needed to verify
that a patient had claimed they were benefiting from medicinal pot.
While
doctors can prescribe pot like it is a pharmaceutical drug, there is a
dearth of clinical evidence on the efficacy of the plant’s touted
benefits and many simply don’t know enough about it to recommend it to
patients. This is complicated by Health Canada refusing to approve
marijuana as a drug or medicine, but being compelled to regulate it by
the courts, which have ruled that Canadians must have reasonable access
to medical cannabis.
Brian Kierans, a
30-year-old TV industry worker in Toronto, said his general practitioner
was too uncomfortable with the new system to give him a prescription
for his irritable bowel syndrome and instead signed a legal medical
document clearing him to get a supply of cannabis at an illegal
dispensary. He eventually secured a prescription from a doctor at a
specialized medical marijuana clinic and now has bought from three
licensed producers.
“The system that’s
set up is set up to be as complicated as possible and, unfortunately,
we’re all just caught in it,” Mr. Kierans said. “And we’re all just
trying to do our best.”
Dr. Cavers said
his association wants Health Canada to offer doctors simpler, much
broader data and guidelines on medicinal cannabis. A Health Canada
representative was unavailable to comment late Thursday, but pointed to the guide the department published for doctors last year.
The
department stated it is actively looking into allegations of
industry-wide kickback fees to doctors, clinics and patient groups for
access to clients that were levelled earlier this week by Tilray,
one of the largest licensed producers. But Dr. Cavers said Health
Canada should also look into the ways doctors are learning about
medicinal marijuana.
About a decade
ago, the Canadian pharmaceutical industry faced stricter guidelines on
how drug company representatives could contact medical professionals,
Dr. Cavers said. That forced those drug companies to support conferences
and events that invite professionals to discuss topics “that are
pertinent to the drugs that they provide,” he added. Much of the
information provided by growers could be very valuable, but it isn’t
from an unbiased source, he said.
Greg
Engel, CEO of Tilray, said in an interview with The Globe and Mail last
week that his company’s representatives will exhibit at about 10 health
care conferences this year. At those conferences, physicians looking for
more information about the system can follow up with Tilray
representatives, he said. Tilray also offers two online programs for
medical professionals to educate themselves on the nuances of the
medical marijuana system.
Tilray broke
away from the industry’s main lobby group to form its own and establish a
code of ethics prohibiting paying any kickbacks. That policy also
states that its members ensure “transparency in the presentation of
research and study results.”
No comments:
Post a Comment